# A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys

> **NCT06582485** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **iCoat Medical AB** · enrollment: 200 (estimated)

## Conditions studied

- Ischemia-reperfusion Injury
- Kidney Transplant; Complications

## Interventions

- **DRUG:** iCM012 solution 2 mg/mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06582485
- **Lead sponsor:** iCoat Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06582485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06582485, "A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06582485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*